Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months...

Related Keywords

United States ,University Of Pennsylvania ,Pennsylvania ,Philadelphia ,Mark Forman ,Madeline Nafus ,Mike Beyer ,William Chou ,University Of Pennsylvania Gene Therapy Program ,Healthcare Communications ,Exchange Commission ,Nasdaq ,Upenn Gene Therapy Program ,Sam Brown Inc ,Passage Bio Inc ,Passage Bio ,Gene Therapy ,Private Securities Litigation Reform Act ,Risk Factors ,Markets ,